Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward

References

• Rodrigues A, Chauhan J, Sagkriotis A, Aasaithambi S, Montrone M. Understanding the lived experience of lung cancer: a European social media listening study. BMC Cancer. 2022;22(1):475. doi:10.1186/s12885-022-09505-4
   PubMed Web of Science ®Google Scholar
• Le Chevalier T. Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going? Ann Oncol. 2010;21(Suppl 7):vii196–vii198. doi:10.1093/annonc/mdq376
   PubMedGoogle Scholar
• Daly ME, Singh N, Ismaila N, et al. Management of stage III non-small-cell lung cancer: ASCO guideline. J Clin Oncol. 2022;40(12):1356–1384. doi:10.1200/JCO.21.02528
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Crino L, Dooms C, et al. 2nd ESMO consensus conference on lung cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol. 2014;25(8):1462–1474. doi:10.1093/annonc/mdu089
   PubMed Web of Science ®Google Scholar
• Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res. 2014;3(4):242–249. doi:10.3978/j.issn.2218-6751.2013.12.05
   PubMedGoogle Scholar
• Huyuk M, Fiocco M, Postmus PE, Cohen D, von der Thusen JH. Systematic review and meta-analysis of the prognostic impact of lymph node micrometastasis and isolated tumour cells in patients with stage I-IIIA non-small cell lung cancer. Histopathology. 2022. doi:10.1111/his.14831
   Web of Science ®Google Scholar
• Gwozdz P, Pasieka-Lis M, Kolodziej K, et al. Prognosis of patients with stages i and ii non-small cell lung cancer with nodal micrometastases. Ann Thorac Surg. 2018;105(5):1551–1557. doi:10.1016/j.athoracsur.2017.12.006
   PubMed Web of Science ®Google Scholar
• Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010;28(19):3138–3145. doi:10.1200/JCO.2009.27.6204
   PubMed Web of Science ®Google Scholar
• Westeel V, Quoix E, Puyraveau M, et al. A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial). Eur J Cancer. 2013;49(12):2654–2664. doi:10.1016/j.ejca.2013.04.013
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–2388. doi:10.1056/NEJMoa0909530
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–2350. doi:10.1056/NEJMoa1809697
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a Phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265. doi:10.1016/S0140-6736(16)32517-X
   PubMed Web of Science ®Google Scholar
• Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7–24. doi:10.1038/s41577-019-0210-z
   PubMed Web of Science ®Google Scholar
• Gerner MY, Casey KA, Mescher MF. Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J Immunol. 2008;181(1):155–164. doi:10.4049/jimmunol.181.1.155
   PubMed Web of Science ®Google Scholar
• Engelhardt JJ, Boldajipour B, Beemiller P, et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell. 2012;21(3):402–417. doi:10.1016/j.ccr.2012.01.008
   PubMed Web of Science ®Google Scholar
• Liu J, Blake SJ, Yong MC, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6(12):1382–1399. doi:10.1158/2159-8290.CD-16-0577
   PubMed Web of Science ®Google Scholar
• Mauguen A, Pignon JP, Burdett S, et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients’ data. Lancet Oncol. 2013;14(7):619–626. doi:10.1016/S1470-2045(13)70158-X
   PubMed Web of Science ®Google Scholar
• Montemurro F, Di Cosimo S. Pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy. Breast. 2014;23(5):690–691. doi:10.1016/j.breast.2014.06.007
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172. doi:10.1016/S0140-6736(13)62422-8
   PubMed Web of Science ®Google Scholar
• Mouillet G, Monnet E, Milleron B, et al. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials. J Thorac Oncol. 2012;7(5):841–849. doi:10.1097/JTO.0b013e31824c7d92
   PubMed Web of Science ®Google Scholar
• Pataer A, Kalhor N, Correa AM, et al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012;7(5):825–832. doi:10.1097/JTO.0b013e318247504a
   PubMed Web of Science ®Google Scholar
• Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378(21):1976–1986. doi:10.1056/NEJMoa1716078
   PubMed Web of Science ®Google Scholar
• Chaft JE, Oezkan F, Kris MG, et al. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med. 2022;28(10):2155–2161. doi:10.1038/s41591-022-01962-5
   PubMed Web of Science ®Google Scholar
• Lee J, Chaft J, Nicholas A, et al. PS01.05 surgical and clinical outcomes with neoadjuvant atezolizumab in resectable stage IB–IIIB NSCLC: LCMC3 trial primary analysis. J Thorac Oncol. 2021;16(3):S59–S61. doi:10.1016/j.jtho.2021.01.320
   Web of Science ®Google Scholar
• Mignard X, Antoine M, Moro-Sibilot D, et al. Inhibiteurs du check-point immunitaire en néo-adjuvant dans les cancers bronchiques non à petites cellules localisés : essai IoNESCO [IoNESCO trial: immune neoajuvant therapy in early stage non-small cell lung cancer]. Rev Mal Respir. 2018;35(9):983–988. French. doi:10.1016/j.rmr.2018.08.006
   PubMedGoogle Scholar
• Cascone T, William WN, Weissferdt A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the Phase 2 randomized NEOSTAR trial. Nat Med. 2021;27(3):504–514. doi:10.1038/s41591-020-01224-2
   PubMed Web of Science ®Google Scholar
• Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(11):1413–1422. doi:10.1016/S1470-2045(20)30453-8
   PubMed Web of Science ®Google Scholar
• Provencio-Pulla M, Nadal E, Larriba JLG, et al. Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial. J Clin Oncol. 2022;40(16_suppl):8501. doi:10.1200/JCO.2022.40.16_suppl.8501
   Google Scholar
• Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–1985. doi:10.1056/NEJMoa2202170
   PubMed Web of Science ®Google Scholar
• Peters S, Kim AW, Solomon B, et al. IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy. Ann Oncol. 2019;30:ii30. doi:10.1093/annonc/mdz064.014
   Google Scholar
• Herbst RS, Majem M, Barlesi F, et al. COAST: an open-label, Phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer. J Clin Oncol. 2022;40(29):3383–3393. doi:10.1200/JCO.22.00227
   PubMed Web of Science ®Google Scholar
• Ricciuti B, Wang X, Alessi JV, et al. Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 2022;8(8):1160–1168. doi:10.1001/jamaoncol.2022.1981
   PubMed Web of Science ®Google Scholar
• Romero A, Nadal E, Serna R, et al. OA20.02 pre-treatment levels of ctDNA for long-term survival prediction in stage IIIA NSCLC treated with neoadjuvant chemo-immunotherapy. J Thorac Oncol. 2021;16(10):S883–S884. doi:10.1016/j.jtho.2021.08.102
   Web of Science ®Google Scholar
• Anagnostou V, Forde PM, White JR, et al. Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. Cancer Res. 2019;79(6):1214–1225. doi:10.1158/0008-5472.CAN-18-1127
   PubMed Web of Science ®Google Scholar
• Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559–574. doi:10.1093/annonc/mdv623
   PubMed Web of Science ®Google Scholar
• Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375–2391. doi:10.1093/annonc/mdv383
   PubMed Web of Science ®Google Scholar
• Tong BC, Gu L, Wang X, et al. Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022;163(2):427–436. doi:10.1016/j.jtcvs.2021.02.099
   PubMed Web of Science ®Google Scholar
• Rothschild SI, Zippelius A, Eboulet EI, et al. SAKK 16/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small-cell lung cancer-a multicenter single-arm Phase II Trial. J Clin Oncol. 2021;39(26):2872–2880. doi:10.1200/JCO.21.00276
   PubMed Web of Science ®Google Scholar